Physician

Jason M Stinnett, MD

According to 2025 Medicare claims, Jason Stinnett, MD (NPI: 1861501694) practices medical oncology in the Ogden, UT market, with the plurality of this provider's patient population coming from Davis, UT. This provider's primary affiliated billing organization is UTAH CANCER SPECIALISTS PC (NPI: 1619925369; TIN: 870519691) and primary practice location at 84041-1274.

Stinnett's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 352 traditional Medicare patients, billed 111,402 HCPCS/CPT codes, and received $1,288,697 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,077 prescription claims across 177 beneficiaries totaling $4,791,220 in drug costs, led by Xtandi (Enzalutamide). 2023 DME data shows 25 claims. Open Payments data shows 9 records totaling $123. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,123,350 to $4,791,220. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,018 and ending at $1,056.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	367	90,241	$1,059,026
2016	391	101,466	$1,496,807
2017	384	128,357	$2,023,930
2018	393	152,810	$1,894,266
2019	396	133,547	$2,288,288
2020	399	127,268	$1,959,104
2021	366	110,359	$1,669,029
2022	380	93,248	$1,636,204
2023	350	110,856	$1,215,268
2024	352	111,402	$1,288,697

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	148	785	$1,123,350
2016	161	759	$930,228
2017	168	916	$1,853,088
2018	155	849	$1,603,968
2019	171	910	$2,047,065
2020	162	909	$2,768,342
2021	180	917	$3,479,077
2022	161	767	$2,909,695
2023	163	833	$2,651,891
2024	177	1,077	$4,791,220

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	38	$1,210
2016	N/R	36	$1,215
2017	N/R	22	$904
2018	N/R	12	$514
2019	N/R	31	$1,132
2020	N/R	39	$1,246
2021	N/R	28	$3,432
2022	N/R	40	$1,639
2023	N/R	25	$1,328
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	147	408	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	195	306	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	99	156	$12
80053	Blood test, comprehensive group of blood chemicals	189	560	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	261	956	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	59	1,770	$846,960
Revlimid	Lenalidomide	41	1,120	$823,731
Ibrance	Palbociclib	51	1,428	$788,903
Imbruvica	Ibrutinib	31	868	$476,183
Jakafi	Ruxolitinib Phosphate	27	810	$447,329

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$123	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	2	$7,071	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Jason M. Stinnett, MD?

Tedicare shows public-source Medicare data for Jason M. Stinnett, MD (NPI 1861501694), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jason M. Stinnett, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jason M. Stinnett, MD?

Jason M. Stinnett, MD is linked to UTAH CANCER SPECIALISTS PC (billing NPI 1619925369) in the available physician profile data.

Does Jason M. Stinnett, MD have Open Payments data?

Jason M. Stinnett, MD has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.